Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$0.25.

  • Foghorn Therapeutics' EPS (Basic) rose 1935.48% to -$0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.13, marking a year-over-year increase of 4114.58%. This contributed to the annual value of -$1.58 for FY2024, which is 3257.29% up from last year.
  • Foghorn Therapeutics' EPS (Basic) amounted to -$0.25 in Q3 2025, which was up 1935.48% from -$0.28 recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year EPS (Basic) high stood at -$0.25 for Q3 2025, and its period low was -$0.77 during Q4 2021.
  • Over the past 5 years, Foghorn Therapeutics' median EPS (Basic) value was -$0.62 (recorded in 2021), while the average stood at -$0.54.
  • Within the past 5 years, the most significant YoY rise in Foghorn Therapeutics' EPS (Basic) was 7827.59% (2021), while the steepest drop was 13043.48% (2021).
  • Quarter analysis of 5 years shows Foghorn Therapeutics' EPS (Basic) stood at -$0.77 in 2021, then grew by 10.39% to -$0.69 in 2022, then grew by 17.39% to -$0.57 in 2023, then skyrocketed by 37.68% to -$0.36 in 2024, then rose by 29.63% to -$0.25 in 2025.
  • Its EPS (Basic) stands at -$0.25 for Q3 2025, versus -$0.28 for Q2 2025 and -$0.3 for Q1 2025.